Androgen-deprivation therapy and risk of death from cardio-vascular disease in prostate cancer patients: a nationwide lithuanian population-based cohort study
Purpose: The main purpose of this study was to evaluate the risk of CVD mortality in the national cohort of patients diagnosed with prostate cancer and treated with ADT compared with the ADT non-users.Materials and methods: We performed a retrospective cohort study of patients aged 40–79 years and d...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2022-12-01
|
| Series: | The Aging Male |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/13685538.2022.2091130 |
| _version_ | 1828397090319892480 |
|---|---|
| author | Justinas Jonušas Mingailė Drevinskaitė Aušvydas Patašius Marius Kinčius Ernestas Janulionis Giedrė Smailytė |
| author_facet | Justinas Jonušas Mingailė Drevinskaitė Aušvydas Patašius Marius Kinčius Ernestas Janulionis Giedrė Smailytė |
| author_sort | Justinas Jonušas |
| collection | DOAJ |
| description | Purpose: The main purpose of this study was to evaluate the risk of CVD mortality in the national cohort of patients diagnosed with prostate cancer and treated with ADT compared with the ADT non-users.Materials and methods: We performed a retrospective cohort study of patients aged 40–79 years and diagnosed with prostate cancer between 1 January 2012 and 31 December 2016 using the Lithuanian Cancer registry data. In total, 13 343 prostate cancer patients were included in the final study cohort who exclusively used gonadotropin-releasing hormone agonists. The primary outcomes that were registered during the follow-up of this study were overall CVD death.Results: There was a higher risk of CVD death in the cohort of patients treated with ADT than in ADT non-users (HR 2.14, 95% CI [1.86–2.45], p < 0.001). Moreover, there was an increased risk of death from ischemic heart disease and stroke (HR 1.42, 95% CI [1.16–1.73] and 1.70, 95% CI [1.18–2.45], respectively) among ADT users. Finally, the risk of CVD-related mortality was highest in the 70–79 age group of ADT users (HR 4.78, 95% CI [3.79–6.04]).Conclusions: This study shows that ADT usage is associated with increased CVD-related mortality risk for patients diagnosed with prostate cancer compared with ADT non-users. The highest mortality risk was found for ischemic heart disease and stroke. CVD-related mortality was increased in the elder group of patients also. |
| first_indexed | 2024-12-10T08:40:01Z |
| format | Article |
| id | doaj.art-8d4eac8772d74415ac572d79174fe85a |
| institution | Directory Open Access Journal |
| issn | 1368-5538 1473-0790 |
| language | English |
| last_indexed | 2024-12-10T08:40:01Z |
| publishDate | 2022-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | The Aging Male |
| spelling | doaj.art-8d4eac8772d74415ac572d79174fe85a2022-12-22T01:55:52ZengTaylor & Francis GroupThe Aging Male1368-55381473-07902022-12-0125117317910.1080/13685538.2022.2091130Androgen-deprivation therapy and risk of death from cardio-vascular disease in prostate cancer patients: a nationwide lithuanian population-based cohort studyJustinas Jonušas0Mingailė Drevinskaitė1Aušvydas Patašius2Marius Kinčius3Ernestas Janulionis4Giedrė Smailytė5Laboratory of Cancer Epidemiology, National Cancer Institute, Vilnius, LithuaniaLaboratory of Cancer Epidemiology, National Cancer Institute, Vilnius, LithuaniaLaboratory of Cancer Epidemiology, National Cancer Institute, Vilnius, LithuaniaLaboratory of Clinical Oncology, National Cancer Institute, Vilnius, LithuaniaExternal Beam Radiotherapy Department, National Cancer Institute, Vilnius, LithuaniaLaboratory of Cancer Epidemiology, National Cancer Institute, Vilnius, LithuaniaPurpose: The main purpose of this study was to evaluate the risk of CVD mortality in the national cohort of patients diagnosed with prostate cancer and treated with ADT compared with the ADT non-users.Materials and methods: We performed a retrospective cohort study of patients aged 40–79 years and diagnosed with prostate cancer between 1 January 2012 and 31 December 2016 using the Lithuanian Cancer registry data. In total, 13 343 prostate cancer patients were included in the final study cohort who exclusively used gonadotropin-releasing hormone agonists. The primary outcomes that were registered during the follow-up of this study were overall CVD death.Results: There was a higher risk of CVD death in the cohort of patients treated with ADT than in ADT non-users (HR 2.14, 95% CI [1.86–2.45], p < 0.001). Moreover, there was an increased risk of death from ischemic heart disease and stroke (HR 1.42, 95% CI [1.16–1.73] and 1.70, 95% CI [1.18–2.45], respectively) among ADT users. Finally, the risk of CVD-related mortality was highest in the 70–79 age group of ADT users (HR 4.78, 95% CI [3.79–6.04]).Conclusions: This study shows that ADT usage is associated with increased CVD-related mortality risk for patients diagnosed with prostate cancer compared with ADT non-users. The highest mortality risk was found for ischemic heart disease and stroke. CVD-related mortality was increased in the elder group of patients also.https://www.tandfonline.com/doi/10.1080/13685538.2022.2091130Prostate cancerandrogen deprivationcardiovascular diseasemortality risk |
| spellingShingle | Justinas Jonušas Mingailė Drevinskaitė Aušvydas Patašius Marius Kinčius Ernestas Janulionis Giedrė Smailytė Androgen-deprivation therapy and risk of death from cardio-vascular disease in prostate cancer patients: a nationwide lithuanian population-based cohort study The Aging Male Prostate cancer androgen deprivation cardiovascular disease mortality risk |
| title | Androgen-deprivation therapy and risk of death from cardio-vascular disease in prostate cancer patients: a nationwide lithuanian population-based cohort study |
| title_full | Androgen-deprivation therapy and risk of death from cardio-vascular disease in prostate cancer patients: a nationwide lithuanian population-based cohort study |
| title_fullStr | Androgen-deprivation therapy and risk of death from cardio-vascular disease in prostate cancer patients: a nationwide lithuanian population-based cohort study |
| title_full_unstemmed | Androgen-deprivation therapy and risk of death from cardio-vascular disease in prostate cancer patients: a nationwide lithuanian population-based cohort study |
| title_short | Androgen-deprivation therapy and risk of death from cardio-vascular disease in prostate cancer patients: a nationwide lithuanian population-based cohort study |
| title_sort | androgen deprivation therapy and risk of death from cardio vascular disease in prostate cancer patients a nationwide lithuanian population based cohort study |
| topic | Prostate cancer androgen deprivation cardiovascular disease mortality risk |
| url | https://www.tandfonline.com/doi/10.1080/13685538.2022.2091130 |
| work_keys_str_mv | AT justinasjonusas androgendeprivationtherapyandriskofdeathfromcardiovasculardiseaseinprostatecancerpatientsanationwidelithuanianpopulationbasedcohortstudy AT mingailedrevinskaite androgendeprivationtherapyandriskofdeathfromcardiovasculardiseaseinprostatecancerpatientsanationwidelithuanianpopulationbasedcohortstudy AT ausvydaspatasius androgendeprivationtherapyandriskofdeathfromcardiovasculardiseaseinprostatecancerpatientsanationwidelithuanianpopulationbasedcohortstudy AT mariuskincius androgendeprivationtherapyandriskofdeathfromcardiovasculardiseaseinprostatecancerpatientsanationwidelithuanianpopulationbasedcohortstudy AT ernestasjanulionis androgendeprivationtherapyandriskofdeathfromcardiovasculardiseaseinprostatecancerpatientsanationwidelithuanianpopulationbasedcohortstudy AT giedresmailyte androgendeprivationtherapyandriskofdeathfromcardiovasculardiseaseinprostatecancerpatientsanationwidelithuanianpopulationbasedcohortstudy |